Results of Phase 2B Clinical Trial Testing New Drug-Resistant TB Treatment Published in Lancet Respiratory Medicine

November 13, 2019 – Results of the Phase 2B trial, known as NC-005 have been published in The Lancet Respiratory Medicine. The NC-005 trial was designed to test the potential of the BPaMZ and BPaZ regimens to shorten therapy in patients with drug-sensitive tuberculosis (TB) and multidrug-resistant TB. NC-005 enrolled 240 patients across 10 sites in Uganda, Tanzania and South Africa. BPaMZ is a four-drug regimen comprised of four presently approved drugs: bedaquiline (B), pretomanid (Pa), moxifloxacin (M), and pyrazinamide (Z). BPaZ is a three-drug regimen consisting of bedaquiline (B), pretomanid (Pa), and pyrazinamide (Z). Based on data from NC-005, the BPaMZ regimen is now being tested in the pivotal SimpliciTB trial. SimpliciTB launched in 2018 and spans four continents. Enrollment is expected to be complete by early 2020.

The release as fetched from its publisher. tballiance.org ↗